Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Sarah Milgrom

Concepts (335)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease
31
2023
118
8.840
 Why?
Positron Emission Tomography Computed Tomography
14
2023
70
3.100
 Why?
Radiotherapy, Intensity-Modulated
14
2019
123
2.540
 Why?
Fluorodeoxyglucose F18
7
2023
125
2.410
 Why?
Antineoplastic Combined Chemotherapy Protocols
28
2023
1361
2.250
 Why?
Radiotherapy
12
2020
177
2.010
 Why?
Lymphoma
8
2021
178
2.000
 Why?
Central Nervous System Neoplasms
9
2021
125
1.990
 Why?
Radiopharmaceuticals
6
2023
187
1.780
 Why?
Neoplasm Staging
30
2021
1178
1.600
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
118
1.560
 Why?
Tumor Burden
5
2023
261
1.540
 Why?
Neoplasm Recurrence, Local
13
2023
863
1.470
 Why?
Lymphoma, Non-Hodgkin
5
2020
72
1.470
 Why?
Sarcoma
2
2023
137
1.440
 Why?
Radiation Injuries
8
2021
127
1.400
 Why?
Lymphoma, Large B-Cell, Diffuse
7
2021
97
1.340
 Why?
Salvage Therapy
10
2020
128
1.290
 Why?
Endometrial Neoplasms
4
2014
151
1.260
 Why?
Mediastinal Neoplasms
5
2021
32
1.240
 Why?
Radiotherapy Dosage
15
2021
246
1.180
 Why?
Combined Modality Therapy
21
2021
1127
1.130
 Why?
Prognosis
22
2023
3339
1.090
 Why?
Hematopoietic Stem Cell Transplantation
6
2023
519
1.060
 Why?
Positron-Emission Tomography
7
2023
284
0.960
 Why?
Radiation
2
2020
24
0.900
 Why?
Radiation Exposure
1
2023
41
0.880
 Why?
Radiotherapy, Adjuvant
6
2019
182
0.870
 Why?
Adenocarcinoma
3
2014
799
0.870
 Why?
Humans
99
2023
115589
0.840
 Why?
Lymphoma, Follicular
5
2020
35
0.830
 Why?
Rhabdomyosarcoma
1
2023
52
0.820
 Why?
Sarcoma, Ewing
1
2023
62
0.800
 Why?
Smiling
1
2021
6
0.800
 Why?
Xerostomia
1
2021
19
0.770
 Why?
Retrospective Studies
36
2023
12608
0.750
 Why?
Brachytherapy
1
2021
104
0.740
 Why?
Aged
41
2020
19250
0.740
 Why?
Chemoradiotherapy
9
2021
187
0.720
 Why?
Proton Therapy
1
2020
10
0.720
 Why?
Middle Aged
48
2020
26998
0.710
 Why?
Neoplasms
3
2023
2118
0.710
 Why?
Aged, 80 and over
21
2020
6417
0.700
 Why?
Face
1
2021
167
0.700
 Why?
Doxorubicin
12
2020
290
0.690
 Why?
Intraocular Lymphoma
2
2016
2
0.680
 Why?
Adult
50
2023
30719
0.670
 Why?
Rectal Neoplasms
3
2016
122
0.650
 Why?
Young Adult
29
2023
10470
0.650
 Why?
Bleomycin
8
2020
232
0.650
 Why?
Lymphoma, B-Cell, Marginal Zone
4
2019
11
0.640
 Why?
Cerebellar Neoplasms
1
2020
131
0.630
 Why?
Vinblastine
8
2020
61
0.620
 Why?
Medulloblastoma
1
2020
172
0.620
 Why?
Dacarbazine
8
2020
100
0.610
 Why?
Recurrence
9
2020
952
0.590
 Why?
Cancer Survivors
1
2021
203
0.580
 Why?
Leukemia, Myeloid, Acute
2
2023
538
0.570
 Why?
Head and Neck Neoplasms
1
2021
425
0.560
 Why?
Meningeal Neoplasms
1
2018
88
0.560
 Why?
Leukemia, Biphenotypic, Acute
1
2016
3
0.560
 Why?
Patient Satisfaction
1
2020
585
0.550
 Why?
Brain Neoplasms
3
2023
980
0.550
 Why?
Breast Neoplasms
5
2019
1872
0.540
 Why?
Female
54
2020
59913
0.520
 Why?
Treatment Outcome
24
2020
9159
0.520
 Why?
Eye Diseases
1
2016
76
0.500
 Why?
Survival Rate
12
2021
1650
0.500
 Why?
Child
14
2023
18489
0.480
 Why?
Follow-Up Studies
15
2020
4440
0.470
 Why?
Glycolysis
3
2023
224
0.470
 Why?
Graft vs Host Disease
1
2016
212
0.470
 Why?
Disease-Free Survival
12
2020
621
0.460
 Why?
Male
48
2021
55949
0.460
 Why?
Stomach Neoplasms
3
2019
66
0.460
 Why?
Adolescent
22
2023
17890
0.450
 Why?
Endometrium
1
2013
59
0.440
 Why?
Peritoneal Cavity
1
2013
23
0.440
 Why?
Digestive System Surgical Procedures
1
2014
89
0.440
 Why?
Lymphoma, B-Cell
3
2021
86
0.440
 Why?
Palate, Hard
1
2012
4
0.430
 Why?
Neoadjuvant Therapy
2
2016
301
0.430
 Why?
Infertility, Female
1
2013
94
0.420
 Why?
Chemoradiotherapy, Adjuvant
3
2019
40
0.420
 Why?
Disease Progression
6
2019
2418
0.420
 Why?
Mastectomy, Simple
1
2012
1
0.420
 Why?
Image Enhancement
1
2013
173
0.410
 Why?
Carcinoma, Lobular
1
2012
44
0.390
 Why?
Sentinel Lymph Node Biopsy
1
2012
98
0.390
 Why?
Carcinoma, Ductal, Breast
1
2012
76
0.390
 Why?
Adrenal Gland Neoplasms
1
2012
81
0.380
 Why?
Organs at Risk
3
2020
30
0.370
 Why?
Tomography, X-Ray Computed
7
2023
2392
0.360
 Why?
Disease Management
6
2019
563
0.350
 Why?
Biopsy
6
2020
1056
0.340
 Why?
Radiotherapy, Image-Guided
3
2019
30
0.340
 Why?
Cellulitis
1
2009
46
0.330
 Why?
Carcinoma, Squamous Cell
1
2014
577
0.320
 Why?
Kaplan-Meier Estimate
7
2020
815
0.320
 Why?
Lymphocytes
3
2020
344
0.320
 Why?
Multiple Myeloma
2
2020
93
0.310
 Why?
Lymphoma, Mantle-Cell
2
2019
18
0.310
 Why?
Survival Analysis
6
2020
1219
0.280
 Why?
Cardiotoxicity
2
2023
28
0.270
 Why?
Pregnancy Complications, Neoplastic
2
2017
50
0.270
 Why?
Patient Selection
2
2022
654
0.270
 Why?
Testicular Neoplasms
2
2018
95
0.270
 Why?
Radiation Pneumonitis
2
2016
24
0.260
 Why?
Magnetic Resonance Imaging
4
2019
3071
0.250
 Why?
Risk Assessment
6
2023
2987
0.250
 Why?
Lymph Node Excision
2
2019
141
0.250
 Why?
Heart
3
2018
608
0.250
 Why?
Antimetabolites, Antineoplastic
2
2017
83
0.240
 Why?
Leukemia
2
2017
209
0.240
 Why?
Risk Factors
5
2021
8697
0.240
 Why?
Central Nervous System
3
2021
239
0.240
 Why?
Mediastinum
3
2019
21
0.230
 Why?
Salivary Glands
2
2021
31
0.230
 Why?
Consensus
2
2023
532
0.230
 Why?
Lymphatic Metastasis
3
2014
276
0.230
 Why?
Lymphadenopathy
1
2023
8
0.220
 Why?
Postoperative Complications
1
2014
2161
0.220
 Why?
Neoplasm Grading
4
2019
244
0.220
 Why?
Remission Induction
3
2018
240
0.210
 Why?
Protons
2
2020
80
0.210
 Why?
Survivors
2
2023
404
0.200
 Why?
Transplantation, Autologous
3
2018
173
0.200
 Why?
Chemotherapy, Adjuvant
2
2013
334
0.200
 Why?
Brain Stem Neoplasms
1
2023
86
0.200
 Why?
Radiometry
2
2019
43
0.200
 Why?
Gastric Mucosa
2
2019
46
0.200
 Why?
Mitogen-Activated Protein Kinase 7
1
2021
15
0.200
 Why?
Multimodal Imaging
3
2017
98
0.200
 Why?
Parotid Gland
1
2021
26
0.190
 Why?
Tooth Abnormalities
1
2021
12
0.190
 Why?
Poly(ADP-ribose) Polymerases
1
2021
88
0.190
 Why?
Radium
1
2020
3
0.190
 Why?
Breath Holding
2
2017
7
0.190
 Why?
Long Term Adverse Effects
1
2020
10
0.180
 Why?
Cranial Irradiation
2
2023
66
0.180
 Why?
Whole-Body Irradiation
1
2020
72
0.170
 Why?
Stem Cell Transplantation
2
2018
151
0.170
 Why?
Cardiology
1
2022
260
0.170
 Why?
Skin Neoplasms
2
2018
761
0.170
 Why?
Child, Preschool
4
2023
9133
0.170
 Why?
Postoperative Care
2
2019
222
0.170
 Why?
Glioma
1
2023
296
0.170
 Why?
Plasmacytoma
1
2019
10
0.170
 Why?
Radiation Dosage
1
2020
139
0.170
 Why?
CD4-CD8 Ratio
1
2018
19
0.160
 Why?
Mycosis Fungoides
1
2018
61
0.160
 Why?
Methotrexate
2
2017
228
0.160
 Why?
Peritoneal Neoplasms
1
2019
54
0.160
 Why?
Electrons
1
2018
72
0.160
 Why?
Area Under Curve
1
2019
278
0.150
 Why?
Breast Neoplasms, Male
1
2018
28
0.150
 Why?
Radiotherapy Setup Errors
1
2017
3
0.150
 Why?
Autografts
1
2018
41
0.150
 Why?
Platelet Count
1
2017
83
0.150
 Why?
Hypothyroidism
1
2018
65
0.150
 Why?
Craniospinal Irradiation
1
2017
4
0.150
 Why?
Dendritic Cell Sarcoma, Follicular
1
2017
2
0.150
 Why?
Vincristine
4
2019
96
0.150
 Why?
Eye Neoplasms
1
2017
15
0.140
 Why?
Leukocyte Count
1
2017
294
0.140
 Why?
Uncertainty
1
2017
97
0.140
 Why?
Predictive Value of Tests
3
2022
1805
0.140
 Why?
Spinal Cord Diseases
1
2017
39
0.140
 Why?
Neoplasm, Residual
1
2017
105
0.140
 Why?
Osteogenesis Imperfecta
2
2007
15
0.140
 Why?
Pentostatin
1
2016
1
0.140
 Why?
Axilla
2
2017
39
0.140
 Why?
Photopheresis
1
2016
9
0.140
 Why?
Anxiety
1
2023
853
0.140
 Why?
Drug Resistance, Neoplasm
2
2019
638
0.130
 Why?
Methylprednisolone
1
2016
83
0.130
 Why?
Collagen Type I
2
2007
110
0.130
 Why?
Plasmablastic Lymphoma
1
2015
6
0.130
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2016
106
0.130
 Why?
Confidence Intervals
1
2016
309
0.130
 Why?
Antibiotics, Antineoplastic
1
2016
114
0.130
 Why?
Congenital Abnormalities
1
2016
74
0.130
 Why?
Abortion, Spontaneous
1
2016
92
0.130
 Why?
Fatal Outcome
1
2016
286
0.130
 Why?
Coronary Artery Disease
1
2021
607
0.130
 Why?
Tacrolimus
1
2016
143
0.130
 Why?
Proportional Hazards Models
4
2020
1087
0.130
 Why?
Biomarkers
4
2021
3467
0.130
 Why?
Hysterectomy
2
2013
118
0.130
 Why?
Transplantation, Homologous
1
2016
397
0.120
 Why?
Blood Platelets
1
2017
350
0.120
 Why?
Age Factors
1
2021
2907
0.120
 Why?
Antineoplastic Agents
4
2019
1893
0.110
 Why?
Caregivers
1
2020
713
0.110
 Why?
Risk
1
2016
819
0.110
 Why?
Kidney Neoplasms
1
2018
326
0.110
 Why?
Etoposide
3
2018
149
0.110
 Why?
Receptors, Progesterone
2
2014
319
0.110
 Why?
Receptor, ErbB-2
2
2014
302
0.110
 Why?
Cyclophosphamide
3
2019
218
0.110
 Why?
Rituximab
3
2019
149
0.110
 Why?
Lung
2
2016
3672
0.110
 Why?
Carcinoma, Non-Small-Cell Lung
1
2021
963
0.110
 Why?
Receptors, Estrogen
2
2014
372
0.110
 Why?
Spinal Cord
1
2015
351
0.110
 Why?
Carboplatin
1
2013
139
0.110
 Why?
Anti-Inflammatory Agents
1
2016
448
0.110
 Why?
Fluorouracil
1
2013
151
0.110
 Why?
Pelvis
1
2013
92
0.110
 Why?
Radiotherapy, Conformal
1
2012
68
0.100
 Why?
Paclitaxel
1
2013
192
0.100
 Why?
Neutrophils
1
2017
1172
0.100
 Why?
Immunosuppressive Agents
1
2016
666
0.100
 Why?
Health Knowledge, Attitudes, Practice
1
2020
1198
0.100
 Why?
Brain
2
2020
2373
0.100
 Why?
Cisplatin
1
2013
263
0.100
 Why?
Immunoenzyme Techniques
1
2012
193
0.100
 Why?
Immunohistochemistry
1
2016
1642
0.100
 Why?
Immunotherapy
1
2015
479
0.100
 Why?
Triple Negative Breast Neoplasms
1
2014
157
0.100
 Why?
Models, Biological
1
2018
1646
0.090
 Why?
Contrast Media
1
2013
362
0.090
 Why?
Liver Neoplasms
1
2014
521
0.090
 Why?
Cohort Studies
5
2018
4944
0.090
 Why?
Prospective Studies
3
2021
6264
0.090
 Why?
Patient Compliance
1
2013
524
0.080
 Why?
Polymorphism, Single Nucleotide
1
2016
1918
0.080
 Why?
Dose-Response Relationship, Radiation
2
2020
130
0.080
 Why?
Lung Neoplasms
1
2021
2207
0.080
 Why?
United States
2
2021
12295
0.080
 Why?
Colorectal Neoplasms
1
2014
617
0.080
 Why?
Antibodies, Monoclonal, Murine-Derived
2
2019
80
0.070
 Why?
Biomarkers, Tumor
1
2014
1048
0.070
 Why?
Prednisone
2
2019
232
0.070
 Why?
Practice Guidelines as Topic
1
2014
1405
0.070
 Why?
Time Factors
4
2018
6165
0.070
 Why?
Cytarabine
2
2018
52
0.070
 Why?
Integrins
1
2007
79
0.070
 Why?
Proteoglycans
1
2007
107
0.070
 Why?
Treatment Failure
2
2018
332
0.070
 Why?
Glycine
1
2006
156
0.060
 Why?
Amino Acid Substitution
1
2006
267
0.060
 Why?
Clinical Decision-Making
2
2019
273
0.060
 Why?
Neoplasm Invasiveness
2
2017
445
0.060
 Why?
X-ray Repair Cross Complementing Protein 1
1
2023
14
0.060
 Why?
Intelligence Tests
1
2023
59
0.060
 Why?
X-Rays
1
2023
31
0.060
 Why?
Phenotype
3
2021
2829
0.050
 Why?
Regression Analysis
2
2016
959
0.050
 Why?
Proto-Oncogene Proteins c-sis
1
2023
35
0.050
 Why?
Inducible T-Cell Co-Stimulator Protein
1
2022
9
0.050
 Why?
Analysis of Variance
2
2016
1227
0.050
 Why?
Cytidine Deaminase
1
2023
57
0.050
 Why?
Brain Stem
1
2023
102
0.050
 Why?
Ribose
1
2021
17
0.050
 Why?
Adenosine Diphosphate
1
2021
81
0.050
 Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
40
0.050
 Why?
Troponin T
1
2021
49
0.050
 Why?
Feedback
1
2021
148
0.050
 Why?
Prevalence
2
2016
2264
0.040
 Why?
Automation
1
2020
74
0.040
 Why?
Neoplasms, Radiation-Induced
1
2020
65
0.040
 Why?
Incidence
2
2016
2335
0.040
 Why?
Neuropsychological Tests
1
2023
919
0.040
 Why?
Risk Management
1
2020
89
0.040
 Why?
Workflow
1
2020
136
0.040
 Why?
Neoplasms, Second Primary
1
2020
91
0.040
 Why?
Mesentery
1
2019
53
0.040
 Why?
Safety
1
2020
298
0.040
 Why?
Busulfan
1
2018
14
0.040
 Why?
Melphalan
1
2018
29
0.040
 Why?
Respiration
1
2019
177
0.040
 Why?
Carmustine
1
2018
47
0.040
 Why?
Inhalation
1
2017
24
0.040
 Why?
Cone-Beam Computed Tomography
1
2017
26
0.040
 Why?
Time-to-Treatment
1
2019
147
0.040
 Why?
Breast
1
2018
138
0.040
 Why?
Subacute Combined Degeneration
1
2017
1
0.040
 Why?
Phosphorylation
1
2021
1571
0.040
 Why?
Deoxycytidine
1
2018
140
0.040
 Why?
Photons
1
2017
57
0.040
 Why?
Organ Sparing Treatments
1
2017
31
0.040
 Why?
Injections, Spinal
1
2017
102
0.040
 Why?
Orbit
1
2017
59
0.030
 Why?
Lymph Nodes
1
2019
423
0.030
 Why?
New York
1
2016
109
0.030
 Why?
Mutation
1
2007
3364
0.030
 Why?
Homocysteine
1
2017
135
0.030
 Why?
Animals
2
2021
32102
0.030
 Why?
Mitochondria
1
2021
750
0.030
 Why?
Procarbazine
1
2015
8
0.030
 Why?
Observer Variation
1
2016
297
0.030
 Why?
Folic Acid
1
2017
159
0.030
 Why?
Transforming Growth Factor beta1
1
2016
156
0.030
 Why?
Genetic Markers
1
2016
325
0.030
 Why?
Texas
1
2016
187
0.030
 Why?
Molecular Targeted Therapy
1
2018
348
0.030
 Why?
Pregnancy
2
2017
5549
0.030
 Why?
Pregnancy Outcome
1
2017
336
0.030
 Why?
Abortion, Induced
1
2016
73
0.030
 Why?
Gastrointestinal Diseases
1
2016
184
0.030
 Why?
Secondary Prevention
1
2016
223
0.030
 Why?
Diagnostic Imaging
1
2017
296
0.030
 Why?
Drug Administration Schedule
1
2016
724
0.030
 Why?
Acute Disease
1
2016
914
0.030
 Why?
Postpartum Period
1
2016
281
0.030
 Why?
CD8-Positive T-Lymphocytes
1
2018
693
0.030
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
269
0.030
 Why?
Mastectomy
1
2014
99
0.030
 Why?
CD4-Positive T-Lymphocytes
1
2018
965
0.030
 Why?
Ultrasonography
1
2016
641
0.030
 Why?
Diagnosis, Differential
1
2017
1357
0.030
 Why?
Multivariate Analysis
1
2016
1440
0.030
 Why?
Medical Oncology
1
2014
230
0.030
 Why?
Ovariectomy
1
2012
117
0.030
 Why?
Comorbidity
1
2016
1473
0.020
 Why?
Severity of Illness Index
1
2019
2578
0.020
 Why?
Quality of Life
1
2021
2385
0.020
 Why?
Electronic Health Records
1
2017
805
0.020
 Why?
Kidney
1
2017
1207
0.020
 Why?
Diet
1
2017
1072
0.020
 Why?
Anti-Bacterial Agents
1
2019
1483
0.020
 Why?
Reproducibility of Results
1
2016
2800
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2125
0.020
 Why?
Infant
1
2020
7979
0.020
 Why?
Case-Control Studies
1
2014
3022
0.020
 Why?
Electrophoresis
1
2006
25
0.020
 Why?
DNA Mutational Analysis
1
2007
372
0.020
 Why?
Databases, Genetic
1
2007
208
0.020
 Why?
Mice
1
2021
15052
0.020
 Why?
Collagen
1
2007
415
0.020
 Why?
Protein Structure, Tertiary
1
2007
804
0.010
 Why?
Binding Sites
1
2007
1177
0.010
 Why?
Protein Binding
1
2007
1917
0.010
 Why?
Cells, Cultured
1
2006
3914
0.010
 Why?
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (335) concept(s)
_
Co-Authors Expand Description
See all (25) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)